Stereotaxis To Report Fourth Quarter And Full Year 2012 Financial Results On March 5, 2013

ST. LOUIS, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2012 fourth quarter and full year ended December 31, 2012 on Tuesday, March 5, 2013 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.

What:	Stereotaxis fourth quarter and full year 2012 financial results conference call
When:	Tuesday, March 5 th at 4:30 p.m. Eastern Time (1:30 p.m. PT)
Dial In Number:	877-941-2068 (US and Canada)
	480-629-9712 (International)
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis' website at www.stereotaxis.com
Call Replay:	A replay of the call will be available approximately one hour following the end of the call through 11:59 p.m. ET on Tuesday, March 12, 2013.
Replay Numbers:	800-406-7325 (US and Canada)
	303-590-3030 (International)
	Replay passcode: 4604310#

About Stereotaxis           

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe ^® ES Remote Magnetic Navigation system, the Odyssey ^® portfolio of lab optimization, networking and patient information management systems and the Vdrive ^™ Robotic Mechanical Navigation system and consumables. 

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The V-Loop ^™ circular catheter manipulator is currently in clinical trials in order to obtain clearance by the U.S. Food and Drug Administration; the Company also is pursuing U.S. clearance for the V-Sono™ ICE catheter manipulator. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com .

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources on a timely basis and on terms that are acceptable, our continued listing on the Nasdaq Global Market, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

CONTACT: Company Contact:
         Michael Kaminski
         Chief Executive Officer
         314-678-6106
         
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300